Market capitalization | $31.68b |
Enterprise Value | $31.77b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 99.62 |
EV/Sales (TTM) EV/Sales | 13.55 |
P/S ratio (TTM) P/S ratio | 13.51 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 89.46% |
Revenue (TTM) Revenue | $2.34b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
31 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:
31 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2,344 2,344 |
89%
89%
|
|
Gross Profit | 2,040 2,040 |
103%
103%
|
|
EBITDA | 158 158 |
120%
120%
|
EBIT (Operating Income) EBIT | 103 103 |
112%
112%
|
Net Profit | -73 -73 |
93%
93%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Yvonne Greenstreet |
Employees | 2,100 |
Founded | 2002 |
Website | www.alnylam.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.